In vitro activity of fleroxacin and 6 other antimicrobials against Acinetobacter anitratus.
The in vitro activity of the 4-quinolone compound fleroxacin (Ro-23-6240) was compared with that of enoxacin, ofloxacin, cefepime (BMY-28142), ceftazidime, ceftriaxone, and tobramycin against a total of 30 recent clinical isolates of Acinetobacter calcoaceticus subsp. anitratum. Susceptibility testing (MIC50/MIC90) was performed by a microtiter broth dilution method and the combination effect of ceftriaxone plus tobramycin was studied by checkerboard titration in microtiter trays. Fleroxacin inhibited most A. calcoaceticus subsp. anitratum at 1 microgram/ml and was as active as enoxacin or tobramycin but slightly less active than ofloxacin (MIC50 = 0.25 microgram/ml; MIC90 = 2.5 microgram/ml) or cefepime (BMY-28142: MIC50 = 0.25 microgram/ml; MIC90 = 1 microgram/ml). Ceftazidime and ceftriaxone were inactive (MIC90 = 8 micrograms/ml and 32 micrograms/ml, respectively). The combination of ceftriaxone plus tobramycin was synergistic in 16.7%, additive in 60%, and indifferent in 23.3%.
Kropec
A
A
Department of Hospital Epidemiology, University Hospital, Freiburg, FRG.
Daschner
F
F
D000150:Acinetobacter / Q000187:drug effects* / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000077723:Cefepime; D002442:Ceftazidime / Q000494:pharmacology; D002443:Ceftriaxone / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D015365:Enoxacin / Q000494:pharmacology; D016576:Fleroxacin; D006801:Humans; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology; D014031:Tobramycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D015365:Enoxacin; D002939:Ciprofloxacin; D002443:Ceftriaxone; D000077723:Cefepime; D002442:Ceftazidime; D015242:Ofloxacin; D016576:Fleroxacin; D014031:Tobramycin